Meeting
2019 ASCO Annual Meeting
Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).
Authors
Hao-Wen Sim
The Kinghorn Cancer Centre, St Vincent's Hospital Sydney, Sydney, Australia
Hao-Wen Sim , Elizabeth Barnes , Zarnie Lwin , Mark Rosenthal , Helen Wheeler , Eng-Siew Koh , Matthew C. Foote , Lauren Fisher , Robyn Leonard , Merryn Hall , John Simes , Mustafa Khasraw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
ACTRN12615000407594
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2042)
DOI
10.1200/JCO.2019.37.15_suppl.2042
Abstract #
2042
Poster Bd #
231
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.
First Author: Ina Ly
Poster
2019 ASCO Annual Meeting
A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).
First Author: Mustafa Khasraw
Poster
2018 ASCO Annual Meeting
A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).
First Author: Mustafa Khasraw
Poster
2018 ASCO Annual Meeting
Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.
First Author: Howard Colman